1<!DOCTYPE html> 2<html lang="en"> 3<head> 4 5 6<title>About Us - Curasight</title> 7<meta property="og:title" content="About Us - Curasight" /> 8<meta name="twitter:title" content="About Us - Curasight" /> 9<link rel="canonical" href="https://www.curasight.com/about-us/"> 10<meta charset="utf-8" /> 11<meta http-equiv="X-UA-Compatible" content="IE=edge" /> 12<meta name="viewport" content="width=device-width, initial-scale=1.0" /> 13<meta property="og:url" content="https://www.curasight.com/about-us/" /> 14<meta name="twitter:url" content="https://www.curasight.com/about-us/" /> 15<meta property="og:type" content="website"/> 16 17<meta name="Description" content="" /> 18<meta property="og:description" content="" /> 19<meta name="twitter:description" content="" /> 20<meta name="twitter:card" content="summary"> 21 22 23<style id="_cssgrid">#_44-2{grid-area:1/1/21/25;}@media(max-width: 768px) {._section-container[data-id^="44-"] ._grid { display: block; }} 24#_12-14{grid-area:1/1/48/25;}@media(max-width: 768px) {._section-container[data-id^="12-"] ._grid { display: block; }} 25#_11-1{grid-area:15/1/41/17;}#_11-3{grid-area:1/1/12/25;}#_11-4{grid-area:1/17/38/25;}#_11-5{grid-area:1/1/15/13;}@media(max-width: 768px){#_11-1{grid-area:14/1/24/13;}#_11-3{grid-area:1/1/12/25;}#_11-4{grid-area:1/13/29/25;}#_11-5{grid-area:1/1/14/13;}}@media(max-width: 667px){#_11-1{grid-area:14/1/24/25;}#_11-3{grid-area:1/1/6/25;}#_11-4{grid-area:24/1/52/25;}#_11-5{grid-area:1/1/14/25;}} 26</style> 27<style id="_iegrid">#_44-2{-ms-grid-row:1;-ms-grid-column:1;-ms-grid-row-span:20;-ms-grid-column-span:24;}#_12-14{-ms-grid-row:1;-ms-grid-column:1;-ms-grid-row-span:47;-ms-grid-column-span:24;}#_11-1{-ms-grid-row:15;-ms-grid-column:1;-ms-grid-row-span:26;-ms-grid-column-span:16;}#_11-3{-ms-grid-row:1;-ms-grid-column:1;-ms-grid-row-span:11;-ms-grid-column-span:24;}#_11-4{-ms-grid-row:1;-ms-grid-column:17;-ms-grid-row-span:37;-ms-grid-column-span:8;}#_11-5{-ms-grid-row:1;-ms-grid-column:1;-ms-grid-row-span:14;-ms-grid-column-span:12;}@media(max-width: 768px){#_11-1{-ms-grid-row:14;-ms-grid-column:1;-ms-grid-row-span:10;-ms-grid-column-span:12;}#_11-3{-ms-grid-row:1;-ms-grid-column:1;-ms-grid-row-span:11;-ms-grid-column-span:24;}#_11-4{-ms-grid-row:1;-ms-grid-column:13;-ms-grid-row-span:28;-ms-grid-column-span:12;}#_11-5{-ms-grid-row:1;-ms-grid-column:1;-ms-grid-row-span:13;-ms-grid-column-span:12;}}@media(max-width: 667px){#_11-1{-ms-grid-row:14;-ms-grid-column:1;-ms-grid-row-span:10;-ms-grid-column-span:24;}#_11-3{-ms-grid-row:1;-ms-grid-column:1;-ms-grid-row-span:5;-ms-grid-column-span:24;}#_11-4{-ms-grid-row:24;-ms-grid-column:1;-ms-grid-row-span:28;-ms-grid-column-span:24;}#_11-5{-ms-grid-row:1;-ms-grid-column:1;-ms-grid-row-span:13;-ms-grid-column-span:24;}}</style> 28 29 30<link rel="stylesheet" href="/main.css?1774614085395" type="text/css"> 31 32 33 34<link rel="apple-touch-icon" sizes="180x180" href="/favicons/apple-touch-icon.png"> 35<link rel="icon" type="image/png" sizes="32x32" href="/favicons/favicon-32x32.png"> 36<link rel="icon" type="image/png" sizes="16x16" href="/favicons/favicon-16x16.png"> 37<link rel="manifest" href="/favicons/site.webmanifest"> 38<link rel="mask-icon" href="/favicons/safari-pinned-tab.svg" color="#446084"> 39<link rel="shortcut icon" href="/favicons/favicon.ico"> 40<meta name="msapplication-TileColor" content="#ffffff"> 41<meta name="msapplication-config" content="/favicons/browserconfig.xml"> 42<meta name="theme-color" content="#ffffff"> 43 44 45 46 47 48 49 50 51 52</head> 53<body class="no-js live page12 sticky-all subnav-type-hover subnav-width-auto nav-thirdlevel-hidden nav-swipe-right nav-toggle-right"> 54 <div id="top"></div> 55 <svg style="display: none;"> 56 <symbol id="svg-Close" viewBox="0 0 44 44"><path d="M38.824 0L44 5.178 5.176 44 0 38.825 38.824 0z" fill="currentColor"></path><path d="M5.176 0L44 38.825 38.824 44 0 5.178 5.176 0z" fill="currentColor"></path></symbol><symbol id="svg-Nav-hide" viewBox="0 0 26 26"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 1024 1024"><path fill="currentColor" d="M0 789q0 5 2 10t5 8q8 8 18.5 8t18.5-8l442-442 443 442q8 8 18.5 8t17.5-8q8-7 8-17.5t-8-18.5L504 310q-7-7-17.5-7t-18.5 7L7 771q-3 4-5 8.5T0 789z"/></svg></symbol>
56<symbol id="svg-Nav-show" viewBox="0 0 26 26"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 1024 1024"><path fill="currentColor" d="M0 329q0-5 2-10t5-9q8-7 18.5-7t18.5 7l442 443 443-443q8-7 18.5-7t17.5 7q8 8 8 18.5t-8 18.5L504 807q-7 8-17.5 8t-18.5-8L7 347q-3-4-5-9t-2-10v1z"/></svg></symbol><symbol id="svg-LinkedIn" viewBox="0 0 1792 1792"><path d="M477 625v991H147V625h330zm21-306q1 73-50.5 122T312 490h-2q-82 0-132-49t-50-122q0-74 51.5-122.5T314 148t133 48.5T498 319zm1166 729v568h-329v-530q0-105-40.5-164.5T1168 862q-63 0-105.5 34.5T999 982q-11 30-11 81v553H659q2-399 2-647t-1-296l-1-48h329v144h-2q20-32 41-56t56.5-52 87-43.5T1285 602q171 0 275 113.5t104 332.5z" fill="currentColor"></path></symbol><symbol id="svg-YouTube-play" viewBox="0 0 147 147"><path d="M73.5 147C32.907 147 0 114.093 0 73.5S32.907 0 73.5 0 147 32.907 147 73.5 114.093 147 73.5 147zm29.01-73.29L55.59 50.327a2 2 0 0 0-2.892 1.79v46.767a2 2 0 0 0 2.892 1.79l46.92-23.384a2 2 0 0 0 0-3.58z" fill="currentColor" fill-rule="evenodd"></path></symbol><symbol id="svg-Search" viewBox="0 0 1792 1792"><path fill="currentColor" d="M1216 832q0-185-131.5-316.5t-316.5-131.5-316.5 131.5-131.5 316.5 131.5 316.5 316.5 131.5 316.5-131.5 131.5-316.5zm512 832q0 52-38 90t-90 38q-54 0-90-38l-343-342q-179 124-399 124-143 0-273.5-55.5t-225-150-150-225-55.5-273.5 55.5-273.5 150-225 225-150 273.5-55.5 273.5 55.5 225 150 150 225 55.5 273.5q0 220-124 399l343 343q37 37 37 90z"/></symbol><symbol id="svg-E-mail" viewBox="0 0 1792 1792"><path d="M1792 710v794q0 66-47 113t-113 47H160q-66 0-113-47T0 1504V710q44 49 101 87 362 246 497 345 57 42 92.5 65.5t94.5 48 110 24.5h2q51 0 110-24.5t94.5-48 92.5-65.5q170-123 498-345 57-39 100-87zm0-294q0 79-49 151t-122 123q-376 261-468 325-10 7-42.5 30.5t-54 38-52 32.5-57.5 27-50 9h-2q-23 0-50-9t-57.5-27-52-32.5-54-38T639 1015q-91-64-262-182.5T172 690q-62-42-117-115.5T0 438q0-78 41.5-130T160 256h1472q65 0 112.5 47t47.5 113z" fill="currentColor"></path></symbol> 57</svg> 58 59 60 61 62<a class="_skiplink" id="_skiptocontent" href="#_main" accesskey="s"><span>Skip to main content</span></a><a class="_skiplink" id="_skiptonav" href="#_mainnav"><span>Skip to navigation</span></a><a class="_skiplink" id="_skiptosearch" href="#"><span>Skip to search</span></a> 63 64<header> 65 <div id="_mobile-header"><a class="_logotype" href="/"><img src="/files/images/curasight-site-logo.png" alt="Curasight"></a><button role="button" id="_toggle-nav" aria-expanded="false" aria-controls="_mobile-menu"> 66 <span> 67 <span class="show">Menu</span> 68 <span class="hide">Close</span> 69 </span> 70 </button></div> 71 <div id="_mobile-menu" class="_mobile-menu"> 72 <div class="_mobile-menu-row _row-0"> 73 <div class="_searchform desktop-lightbox mob-regular"> 74 <form action="/search/"> 75 <input aria-label="Search" class="_searchbox" placeholder="Search" name="q" value="" autocomplete="off" /><button aria-label="Submit search"><svg role="img" width="1792" height="1792" viewBox="0 0 1792 1792"> 76 <use xlink:href="#svg-Search"></use> 77 </svg></button> 78 <div class="_instantsearch" data-nohits="No results found"></div> 79 </form> 80 81 <button class="_toggleSearch" aria-hidden="true"><svg role="img" width="1792" height="1792" viewBox="0 0 1792 1792"> 82 <use xlink:href="#svg-Search"></use> 83 </svg></button> 84 85 </div> 86</div> 87 <div id="_desktop-header"><div class="_cell-0-0"></div><div class="_cell-0-1"><a href="/investor/the-share/" id="_ticker"><div class="ticker"> 88 <div class="_ticker-text"> 89 <strong><span class="_ticker-price"> </span> DKK</strong> 90 <span class="_ticker-changePerc"> </span>% 91 | <span data-tickerformat="D MMM, YYYY" data-when="QuoteTime"></span> 92 </div> 93</div> 94</a><!-- --></div><div class="_cell-0-2"></div><div class="_cell-1-0"></div><div class="_cell-1-1"><a class="_logotype" href="/"><img src="/files/images/curasight-site-logo.png" alt="Curasight"></a><nav id="_mainnav" aria-label="Main navigation"> 95<ul id="_menu1" class="level1" data-togglelabel="Toggle navigation"><li class="expanded selected"><a href="/about-us/">About Us</a><ul id="_menu12" class="level2" aria-hidden="true"><li><a href="/about-us/our-motivation/">Our Motivation</a></li><li><a href="/about-us/management-team/">Management Team</a></li><li><a href="/about-us/board-of-directors/">Board of Directors</a></li><li><a href="/about-us/history/">History</a></li></ul></li><li><a href="/upar-the-target/">uPAR â the Target</a><ul id="_menu16" class="level2" aria-hidden="true"><li><a href="/upar-the-target/upar-theranostics/">uPAR Theranostics</a></li><li><a href="/upar-the-target/utrace/">uTRACE®</a></li><li><a href="/upar-the-target/utreat/">uTREAT®</a></li><li><a href="/upar-the-target/disease-areas/">Disease Areas</a></li><li><a href="/upar-the-target/publications/">Publications</a></li></ul></li><li><a href="/pipeline/">Pipeline</a></li><li><a href="/news/">News and Media</a><ul id="_menu27" class="level2" aria-hidden="true"><li><a href="/news/press-releases/">Press releases</a></li><li><a href="/news/presentations/">Presentations</a></li><li><a href="/news/subscribe/">Subscribe</a></li><li><a href="/news/frequently-asked-questions/">FAQ</a></li></ul></li><li><a href="/investor/">Investor</a><ul id="_menu22" class="level2" aria-hidden="true"><li><a href="/investor/curasight-as-an-investment/">Curasight as an investment</a></li><li><a href="/investor/reports/">Financial reports</a></li><li><a href="/investor/the-share/">The Share</a></li><li><a href="/investor/general-meetings/">General meetings</a></li><li><a href="/investor/calendar/">Calendar</a></li><li><a href="/investor/events/">Events</a></li><li><a href="/investor/corporate-governance/">Corporate Governance</a></li><li><a href="/investor/analyst-coverage/">Analysts</a></li><li><a href="/investor/archive-financing/">Archive financing</a></li></ul></li><li><a href="/contact/">Contact</a></li></ul></nav>
96 <div class="_searchform desktop-lightbox mob-regular"> 97 <form action="/search/"> 98 <input aria-label="Search" class="_searchbox" placeholder="Search" name="q" value="" autocomplete="off" /><button aria-label="Submit search"><svg role="img" width="1792" height="1792" viewBox="0 0 1792 1792"> 99 <use xlink:href="#svg-Search"></use> 100 </svg></button> 101 <div class="_instantsearch" data-nohits="No results found"></div> 102 </form> 103 104 <button class="_toggleSearch" aria-hidden="true"><svg role="img" width="1792" height="1792" viewBox="0 0 1792 1792"> 105 <use xlink:href="#svg-Search"></use> 106 </svg></button> 107 108 </div> 109</div><div class="_cell-1-2"></div></div> 110 111 </div> 112</header> 113 114<nav class="breadcrumb" aria-label="Breadcrumb"><ul><li><a href="/">Home</a></li><li><p>About Us</p></li></ul></nav> 115 116 <div id="_middleregion"><div id="_leftregion"> 117 <div data-id="44-1" class="_section-container"> 118 119 <div class="_section"> 120 <div class="_grid"> 121 122 <div id="_44-2" class="_block"> 123 124 125 <div class="_block-content"> 126 127<nav id="subnav" aria-label="Section"> 128<h2><a href="/about-us/">About Us</a></h2><ul><li><a href="/about-us/our-motivation/">Our Motivation</a></li><li><a href="/about-us/management-team/">Management Team</a></li><li><a href="/about-us/board-of-directors/">Board of Directors</a></li><li><a href="/about-us/history/">History</a></li></ul> 129</nav> 130 </div> 131 132 133 </div> 134 135 </div> 136 </div> 137 138 </div> 139 </div><main id="_main"> 140 <div data-id="12-1" class="_section-container"> 141 142 <div class="_section"> 143 <div class="_grid"> 144 145 <div id="_12-14" class="_block"> 146 147 148 <div class="_block-content"> 149 <h1>About Curasight</h1> 150<p><strong>First-in-Class Radioligand Therapy Targeting uPAR â the Driver of Cancer Aggressiveness</strong></p> 151<p>Curasight is a clinical-stage radiopharmaceutical company developing uTREAT<sup>®</sup>, a first-in-class uPAR-targeted radioligand therapy (RLT) designed to treat aggressive solid tumors across multiple indications.</p> 152<p>uPAR (urokinase-type plasminogen activator receptor) is broadly expressed in aggressive cancers and is associated with invasion, angiogenesis, and metastasis, enabling a platform-based development strategy built on a shared biological target and shared uPAR-targeting ligand. One target. One therapy. A pipeline-in-a-drug across aggressive solid tumors.</p> 153<p>Curasightâs therapeutic platform, uTREAT<sup>®</sup>, is supported by uTRACE<sup>®</sup>, our clinically validated uPAR PET diagnostic platform built on the same uPAR-targeting ligand. uTRACE<sup>®</sup> enables a true theranostic approach by supporting patient selection, confirming tumor targeting, and de-risking therapeutic development through human imaging validation. uTRACE<sup>®</sup> is fully developed, GMP-manufactured, and has been evaluated in nine clinical trials involving 450 patients across eight different solid tumor types. This extensive clinical experience provides direct human validation of uPAR as a therapeutic target and demonstrates robust tumor uptake and favorable biodistribution â forming the foundation for uTREAT<sup>®</sup>.</p> 154<p>The platform is built on more than a decade of rigorous translational research conducted at Copenhagen University Hospital and the University of Copenhagen, providing a strong academic and clinical foundation for Curasightâs first-in-class uPAR targeting approach.</p> 155<p>Together, this combination of validated biology, the right radioligand modality, and human clinical proof-of-concept positions uTREAT<sup>®</sup> as a next-generation radioligand therapy platform.</p> 156 </div> 157 158 159 </div> 160 161 </div> 162 </div> 163 164 </div> 165 </main></div><footer> 166 <div data-id="11-1" class="_section-container background-mediumgrey space"> 167 168 <div class="_section"> 169 <div class="_grid"> 170 171 <div id="_11-5" class="_block"> 172 173 174 <div class="_block-content"> 175 176<img src="/files/images/curasight-site-logo.png" alt="Curasight" class="footer-logo" /> 177 178 </div> 179 180 181 </div> 182 183 <div id="_11-4" class="_block"> 184 185 186 <div class="_block-content"> 187 <h2>Subscribe</h2><p>Subscribe to get the latest news first.</p> 188 189<form action="//publish.ne.cision.com/Subscription/Subscribe" method="post" class="_subscribe"> 190 <input type="hidden" name="subscriptionUniqueIdentifier" value="3094420cd5"/> 191 <input type="hidden" name="Replylanguage" value="en"/> 192 <div class="_fields"> 193 <div id="973969405774965"></div> 194 <input style="display: none;" name="Language" type="checkbox" checked value="en"> 195 <h3>Choose type</h3> 196 <div class="types"> 197 198 <label><input name="informationtype" type="checkbox" value="kmk,rpt,rdv"><span>Financial reports</span></label> 199 200 <label><input name="informationtype" type="checkbox" value="prm"><span>Press releases</span></label> 201 202 </div> 203 <label>
204 <span>E-mail</span> 205 <input required type="email" name="Email" placeholder="E-mail"> 206 <div class="_result _fail">Something went wrong - please make sure you entered the correct email.</div> 207 </label> 208 209 <div class="_privacynotice"><p><em data-renderer-mark="true">I consent to Curasight handling my personal data. See Curasight's <a data-testid="link-with-safety" href="/terms-of-use/" title="/terms-of-use/" data-renderer-mark="true" class="css-1rn59kg">Terms of Use</a> for information about how we handle personal data.</em></p></div><button><span>Subscribe</span></button> 210 </div> 211 <div class="_result _success">Thank you. You will get an e-mail message to activate your subscription.</div> 212</form> 213 214 215 </div> 216 217 218 </div> 219 220 <div id="_11-1" class="_block"> 221 222 223 <div class="_block-content"> 224 <p>Curasight is a clinical-stage radiopharmaceutical company advancing uTREAT<sup>®</sup>, a first-in-class uPAR-targeted radioligand therapy (RLT) designed to treat aggressive solid tumors across multiple indications. uTREAT<sup>®</sup> is supported by the clinically validated imaging agent uTRACE<sup>®</sup>, built on the same uPAR-targeting ligand, enabling a differentiated and de-risked theranostic approach.</p> 225<p>uPAR (urokinase-type plasminogen activator receptor) is broadly expressed in aggressive cancers and plays a central role in tumor invasion, angiogenesis, and metastasis. By focusing on this validated and widely expressed target, Curasight is pursuing a therapeutic strategy across multiple high-unmet-need solid tumors using a shared biological target and targeting ligand.</p> 226<p><strong>One target. One therapy. A pipeline-in-a-drug across aggressive solid tumors.</strong></p> 227 </div> 228 229 230 </div> 231 232 </div> 233 </div> 234 235 </div> 236 237 <div data-id="11-2" class="_section-container background-darkgrey"> 238 239 <div class="_section"> 240 <div class="_grid"> 241 242 <div id="_11-3" class="_block"> 243 244 245 <div class="_block-content"> 246 247 248<div class="footer--bottom"> 249 250 <a href="#top" class="back-to-top"> 251 <svg role="img" aria-label="Back to top" width="16" viewB
251ox="0 0 26 26"><use xlink:href="#svg-Nav-hide"></use></svg> 252 </a> 253 254 <ul class="footer__nav"><li><a href="/news/">News and Media</a></li><li><a href="/contact/">Contact</a></li><li><a href="/terms-of-use/">Terms of use</a></li></ul> 255 256 257 <p class="footer__copyright">Copyright 2026 © <strong>Curasight</strong></p> 258 259</div> 260 261 262 263 264 265 266 267 268 269 </div> 270 271 272 </div> 273 274 </div> 275 </div> 276 277 </div> 278 </footer> 279 280<div id="_cookiebanner-opt-in-out" class="hidden _cookiebanner-opt-in-out" data-nosnippet="true"> 281 <div class="_cookiebanner-opt-in-out--inner"> 282 <p>This website uses cookies to provide the best possible user experience. If you continue without making any changes you allow this. 283<a href="/terms-of-use/">Read more about cookies here</a></p> 284 <div class="_cookie-buttons"> 285 <button><span>Accept</span></button> 286 </div> 287 288 289 290 </div> 291 292</div> 293 294 295 296
297<script nonce="7IT9y9q0npWrl1QbptfM5w==">window.waasconfig = {"lang":"en","pageId":12,"template":1,"gaoptout":true,"consentFunctions":[],"initFunctions":[],"cleanupFunctions":[],"optout":true,"plausible":"curasight.com","thousandDelimiter":"","decimalSign":"","youtubedisclaimer":"","youtubeaccept":"","vimeodisclaimer":"","vimeoaccept":"","mapsdisclaimer":"","mapsaccept":""};</script>
297<script src="/main.js?1774614054815"></script>
297 298 299 300
300<script defer src="/api/analytics/"></script>
300 301 302 <div class="overlay-cover"></div> 303 <div class="overlay" aria-hidden="true"> 304 <div class="overlay__outer"> 305 <div class="overlay__inner"> 306 <button class="overlay__close">Close</button> 307 <div class="overlay__content"></div> 308 </div> 309 </div> 310 </div> 311</body> 312</html>
Line numbers count LF bytes from the start of the resource, as the search results do. Vendor segments are library code the classifier recognised; they are stored but not indexed. Bytes are shown as Latin1 characters, one per byte.